Introduction to Akadeum’s Biotech Showcase Presentation
ANN ARBOR, Mich., January 8, 2026 — Akadeum Life Sciences, the industry leader in buoyant microbubble cell separation technology, announced that Chief Executive Officer Brandon McNaughton, PhD, will deliver a groundbreaking presentation at Biotech Showcase™ 2026 in San Francisco, California, on January 12, 2026. This highly anticipated presentation will showcase how Akadeum’s innovative microbubble platform is revolutionizing the cell therapy manufacturing landscape, offering solutions that could fundamentally transform treatment accessibility for millions of patients worldwide.
Dr. McNaughton’s presentation will demonstrate how Akadeum’s scalable microbubble technology addresses critical manufacturing bottlenecks currently limiting cell therapy expansion. The platform has shown remarkable potential to enable the production of hundreds of thousands of cell therapy doses annually, a dramatic increase from current manufacturing capacities that restrict treatment availability to only select patient populations.
Addressing Industry Challenges Through Innovation
The presentation will specifically focus on how Akadeum’s manufacturing solution helps overcome persistent industry challenges, including high production costs, lengthy manufacturing timelines, and limited scalability. These innovations are particularly significant as the healthcare industry seeks to expand cell therapies beyond rare cancers into larger patient populations affected by autoimmune diseases, solid tumors, diabetes, and other high-prevalence conditions that affect millions globally.
Revolutionary Microbubble Technology Platform
Akadeum’s patented microbubble technology represents a paradigm shift in cell separation methodology. Unlike traditional magnetic bead-based approaches, Akadeum’s system uses gentle buoyancy forces to float unwanted cells to the surface, creating the only truly scalable negative selection workflow available in the market today. This innovative approach yields completely untouched target cells with significantly enhanced viability and increased therapeutic potency.
Technical Advantages of Buoyant Separation
The microbubble platform delivers superior performance across multiple critical parameters. By eliminating the mechanical stress associated with magnetic separation, the technology preserves cell membrane integrity and maintains natural cell receptor expression. This gentler process results in higher-quality therapeutic cells that demonstrate improved expansion capabilities and enhanced functional activity in downstream applications.
The technology’s scalability extends from research-scale applications processing millions of cells to commercial manufacturing handling over 100 billion cells per batch, maintaining consistent performance and quality throughout the entire scale range.
Single-Day Cell Therapy Manufacturing Breakthrough
Akadeum’s microbubbles have solved a fundamental challenge in cell therapy production: manufacturing time. Traditional workflows requiring multiple days of processing can now be compressed into a single day, dramatically accelerating patient access to life-saving treatments.
Partnership with Kure Cells
Kure Cells, a pioneering company in rapid CAR-T therapy development, has integrated Akadeum’s technology into their manufacturing platform to achieve unprecedented single-day production timelines. David Wald, CEO of Kure Cells, emphasized the transformative impact: “At Kure Cells, our mission is to make CAR-T therapies faster, more accessible, and more affordable. Akadeum’s cell isolation technology directly supports this mission by simplifying a traditionally complex step in manufacturing, enabling speed, consistency, and scalability without sacrificing cell quality.”
Clinical Applications and Patient Impact
This dramatic reduction in manufacturing time has profound implications for patient care. Faster production means reduced wait times for critically ill patients, lower logistical complexity, and the potential for outpatient treatment settings. For patients with rapidly progressing diseases, the ability to receive therapy within days rather than weeks could significantly improve treatment outcomes and survival rates.
Cost Efficiency and Return on Investment
Akadeum’s microbubble technology delivers exceptional financial advantages for cell therapy manufacturers. Comprehensive data generated in collaboration with industry leaders demonstrates that microbubble-enabled workflows achieve 40% overall cost savings compared to traditional magnetic separation approaches.
Multiple Dimensions of Cost Reduction
These substantial savings result from several key factors:
Labor Efficiency: Simplified workflows reduce hands-on processing time and technical complexity, decreasing labor costs and training requirements while minimizing human error potential.
GMP Space Optimization: The technology’s smaller footprint requires significantly less cleanroom space, reducing expensive GMP facility costs and enabling more efficient facility utilization.
Capital Equipment Savings: Elimination of specialized magnetic separation equipment requirements removes substantial upfront capital investments and ongoing maintenance expenses.
Unmatched Return on Investment Profile
The combination of reduced operational costs, eliminated equipment expenses, and improved cell quality creates an unprecedented ROI profile for manufacturers. This economic advantage becomes even more pronounced at commercial scale, where the technology maintains consistency and enhanced performance across batches processing up to 100+ billion cells.
The smaller manufacturing footprint also enables deployment in outpatient settings and community hospitals, dramatically expanding treatment accessibility beyond specialized academic medical centers.
Impact on Patient Accessibility and Treatment Expansion
The scalability and cost-effectiveness of Akadeum’s platform are critical enablers for expanding cell therapy access to larger patient populations. Current cell therapy manufacturing constraints limit treatments primarily to rare cancers with small patient numbers and high price points exceeding $400,000 per patient.
Expanding Into High-Prevalence Indications
Akadeum’s technology makes manufacturing economically viable for high-prevalence conditions including:
Autoimmune Diseases: Conditions like lupus, rheumatoid arthritis, and multiple sclerosis affect millions of patients who could potentially benefit from cell therapy approaches.
Solid Tumors: Common cancers including breast, lung, and colon cancers represent enormous patient populations where improved manufacturing economics could enable broader treatment access.
Diabetes: Both Type 1 and Type 2 diabetes, affecting hundreds of millions globally, are targets for emerging cell therapy approaches that require scalable manufacturing solutions.
Future of Scalable Cell Therapy Production
Akadeum’s presentation at Biotech Showcase 2026 represents more than a technology demonstration—it signals a fundamental shift in how the industry approaches cell therapy manufacturing. The combination of speed, quality, scalability, and cost-effectiveness positions microbubble technology as an essential platform for the next generation of cell therapies.
As the industry moves toward treating larger patient populations with diverse conditions, manufacturing innovations like Akadeum’s microbubbles will be critical to realizing the full potential of personalized medicine and making these transformative therapies accessible to patients worldwide.
